Avitene Microfibrillar Collagen Hemostat (MCH) Flour; Avitene Microfibrillar Collagen Hemostat (MCH) UltraFoam; Avitene
Davol Inc., Sub. C. R. Bard, Inc. · Decision date Jul 15, 2026
What did the FDA decide?
FDA records N17600/S047 as a supplement to PMA null, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 15, 2026.
FDA approval order statement
updated water system equipment for the Woburn, MA manufacturing site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jul 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- N17600/S047
- Regulatory pathway
- PMA supplement
- Applicant
- Davol Inc., Sub. C. R. Bard, Inc.
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Jul 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Davol Inc., Sub. C. R. Bard, Inc.
- Product code
- LMF
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N17600/S047 received
Application receipt date recorded by FDA.
N17600/S047 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| C.R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Davol Inc., Sub. C. R. Bard, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Crossings Blvd., Warwick, RI, 02886
Sources and methodology
- Original FDA record: N17600/S047
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

